Posts - Bill - S 1637 MVP Act
senate 05/07/2025 - 119th Congress
We are working to establish clear rules for value-based purchasing arrangements in Medicaid, aiming to improve how drug prices are reported and to promote payment models that link costs to patient outcomes. This legislation seeks to make these arrangements more transparent and accessible across states while encouraging more effective and affordable treatments.
Congress.gov
S 1637 - MVP Act
Views
right-leaning 05/07/2025
Sounds like another layer of government meddling in our free market—let the market price drugs, not bureaucrats.
moderate 05/07/2025
A thoughtful nudge towards smarter drug spending—let's see if states and companies actually play ball.
left-leaning 05/07/2025
Finally, a bill that tries to tie drug prices to real patient outcomes—talk about putting people over profits!
right-leaning 05/07/2025
Value-based purchasing? More like value-based overreach—leave innovation and pricing to pharma, not politicians.
left-leaning 05/07/2025
Value-based purchasing in Medicaid? Sounds like a win for both patients and taxpayers tired of corporate greed.
moderate 05/07/2025
Sounds promising: pay for results, not just pills—but the proof’s in the policy pudding.
right-leaning 05/07/2025
Medicaid reforms that sound good on paper but could drown providers in red tape and kill innovation.
moderate 05/07/2025
If price tags danced with outcomes, maybe Medicaid could catch a healthier break.
left-leaning 05/07/2025
If keeping Big Pharma accountable is MVP, then this bill deserves a standing ovation from the left.